Compare Recursion Pharmaceuticals Inc (RXRX) vs ThredUp Inc (TDUP) Price & Performance

RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.

Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.

ThredUp (TDUP) trades at $2.67, down 1.84% on the day, amid a bearish technical signal. The company reported a Q2 2026 GAAP loss of $0.05 per share, missing the expected $0.03 loss, and cut its full-year revenue outlook, citing promotional headwinds. Despite a high gross margin of 79.52%, the firm remains unprofitable with a net income margin of -6.65%. Recent news includes participation in investor conferences and the launch of a peer-to-peer marketplace, but also multiple law firm investigations into securities claims following the earnings miss.

The outlook is clouded by persistent losses and competitive pressures, though analyst consensus leans Buy (57% of 14 analysts). Key risks include execution on profitability, the sustainability of revenue growth, and potential legal overhangs. The stock's trajectory hinges on demonstrating a clear path to net income positivity amid a challenging retail environment.